Skip to main content

Table 1 Demographic and clinical characteristics of the Alzheimer’s disease patient group and control groups

From: Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer’s disease

 

Alzheimer’s disease

Normal Control

Normal range

Total

(n = 32)

Subgroup for analysis between [18F] BCPP and [11C]PBB3 PET

(n = 16)

[18F] BCPP PET

(n = 17)

[11C]PBB3 PET

(n = 18)

Age (years)

71.1 ± 8.3

71.3 ± 5.4

66.6 ± 9.4

69.5 ± 8.8

 

Men/women (number)

11/21

4/12

10/7

8/10

 

Disease duration (years)

2.8 ± 1.1

2.4 ± 0.8

   

Clinical Dementia Rating (0/0.5/1)

0/20/12

0/12/4

17/0/0

18/0/0

 

Mini-Mental State Examination (/30)

22.2 ± 4.1

22.8 ± 3.7

27.5 ± 1.9

27.4 ± 1.9

> 23

Wechsler Memory Scale-Revise logical memory II (delayed recall) (story A and B) (/50)

5.4 ± 5.3

6.8 ± 5.8

  

> 11

Frontal Assessment Battery (/18)

10.1 ± 2.6

10.7 ± 2.0

   

Self-rating Depression Scale (/100)

36.9 ± 8.6

37.6 ± 8.3

  

< 60

Regional [18F] BCPP-EF standardized uptake value ratio (Braak I-II / III-IV/ V-VI ROI)

0.59 ± 0.06/

0.85 ± 0.05/

0.89 ± 0.04

0.61 ± 0.04/

0.84 ± 0.03/

0.88 ± 0.03

0.63 ± 0.03/0.89 ± 0.02/0.93 ± 0.03

  

Regional [11C]PBB3 PET binding potential (Braak I-II / III-IV/ V-VI ROI)

0.25 ± 0.08/

0.38 ± 0.13/

0.31 ± 0.11

0.25 ± 0.08/

0.38 ± 0.13/

0.31 ± 0.11

 

0.16 ± 0.07/

0.22 ± 0.09/

0.17 ± 0.08

 

Regional [11C] PiB PET standardized uptake value ratio (Braak I-II / III-IV/ V-VI ROI)

1.31 ± 0.17/

1.69 ± 0.24/

1.78 ± 0.25

1.39 ± 0.17/

1.67 ± 0.25/

1.78 ± 0.24

   

[11C] PiB PET global cortical standardized uptake value ratio

1.88 ± 0.24

1.89 ± 0.21

  

< 1.4

[11C]PBB3 PET global cortical binding potential

0.38 ± 0.11

0.38 ± 0.11

 

0.17 ± 0.05

 

Cerebrospinal fluid

     

Total tau (pg/ml)

712.1 ± 207.2

   

< 1200

Phospho-tau (pg/ml)

86.7 ± 26.1

   

< 50

  1. Data are presented as mean ± SD (range)
  2. To confirm tau pathology, sixteen out of thirty-two patients completed [11C]PBB3 PET scan. The rest of sixteen patients underwent cerebrospinal fluid tests